Comparison of Tobramycin and Moxifloxacin eye drops in acute bacterial conjunctivitis: An open label randomized controlled institutional study from Kolkata

P. Banerjee, M. Chowdhury, Souradeep Ray, S. Chatterjee, S. Basak, A. Das
{"title":"Comparison of Tobramycin and Moxifloxacin eye drops in acute bacterial conjunctivitis: An open label randomized controlled institutional study from Kolkata","authors":"P. Banerjee, M. Chowdhury, Souradeep Ray, S. Chatterjee, S. Basak, A. Das","doi":"10.5455/jmas.111700","DOIUrl":null,"url":null,"abstract":"Received 04 June 2020 Revised 24 June 2020 Accepted 07 July 2020 Online 20 July 2020 Print 31 July 2020 Topical antibiotics are used empirically to hasten the clinical cure and prevent transmission. Tobramycin and Moxifloxacin eye drops are frequently prescribed but head to head clinical comparison was not documented from eastern India. This study was aimed to compare the efficacy and safety of both antibiotics in suspected acute bacterial conjunctivitis. This study was conducted from February 2019 to May 2019. 150 patients with suspected bacterial conjunctivitis were randomized into two groups to receive either Tobramycin sulphate 0.3% W/V or Moxifloxacin 0.5% W/V eye drops 4 times daily in the effected eye for a period of seven days in an open label manner. All participants were allowed to simultaneously apply tear substitute (Carboxymethylcellulose sodium 0.5% W/V) in both eyes thrice daily. Efficacy was measured on day 3 and 7 in terms of clinical cure rate which was defined as absence of any eye sign of conjunctivitis. Safety of the drugs was assessed by the overall ocular adverse events reported by the patients. 61 patients from Tobramycin group and 66 from Moxifloxacin group completed the full study. High clinical cure rates were achieved with both agents although it was slightly higher with Moxifloxacin on day 3 (56.06% versus 47.54%; p=0.37) as well as on day 7 (93.94% versus 88.52%; p=0.52) of follow up. A single case of slight blurring of vision was reported with Tobramycin, while another patient complained of mild irritation on eyes from Moxifloxacin group. Overall ocular adverse effects were very mild and comparable. Both Tobramycin sulphate 0.3% W/V and Moxifloxacin 0.5% W/V eye drops are equally effective as empirical therapy when used in acute bacterial conjunctivitis for seven days four times daily with causing negligible side effects. Corresponding author","PeriodicalId":16176,"journal":{"name":"Journal of Medical and Allied Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical and Allied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/jmas.111700","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Received 04 June 2020 Revised 24 June 2020 Accepted 07 July 2020 Online 20 July 2020 Print 31 July 2020 Topical antibiotics are used empirically to hasten the clinical cure and prevent transmission. Tobramycin and Moxifloxacin eye drops are frequently prescribed but head to head clinical comparison was not documented from eastern India. This study was aimed to compare the efficacy and safety of both antibiotics in suspected acute bacterial conjunctivitis. This study was conducted from February 2019 to May 2019. 150 patients with suspected bacterial conjunctivitis were randomized into two groups to receive either Tobramycin sulphate 0.3% W/V or Moxifloxacin 0.5% W/V eye drops 4 times daily in the effected eye for a period of seven days in an open label manner. All participants were allowed to simultaneously apply tear substitute (Carboxymethylcellulose sodium 0.5% W/V) in both eyes thrice daily. Efficacy was measured on day 3 and 7 in terms of clinical cure rate which was defined as absence of any eye sign of conjunctivitis. Safety of the drugs was assessed by the overall ocular adverse events reported by the patients. 61 patients from Tobramycin group and 66 from Moxifloxacin group completed the full study. High clinical cure rates were achieved with both agents although it was slightly higher with Moxifloxacin on day 3 (56.06% versus 47.54%; p=0.37) as well as on day 7 (93.94% versus 88.52%; p=0.52) of follow up. A single case of slight blurring of vision was reported with Tobramycin, while another patient complained of mild irritation on eyes from Moxifloxacin group. Overall ocular adverse effects were very mild and comparable. Both Tobramycin sulphate 0.3% W/V and Moxifloxacin 0.5% W/V eye drops are equally effective as empirical therapy when used in acute bacterial conjunctivitis for seven days four times daily with causing negligible side effects. Corresponding author
妥布霉素和莫西沙星滴眼液治疗急性细菌性结膜炎的比较:加尔各答的一项开放标签随机对照机构研究
2020年7月7日在线2020年7月20日印刷2020年7月31日外用抗生素是经验性使用,以加速临床治疗和预防传播。妥布霉素和莫西沙星滴眼液经常被开处方,但在印度东部没有记录头对头的临床比较。本研究旨在比较两种抗生素治疗疑似急性细菌性结膜炎的疗效和安全性。该研究于2019年2月至2019年5月进行。150例疑似细菌性结膜炎患者随机分为两组,每天4次,以开放标签的方式在患眼滴注硫酸妥布霉素0.3% W/V或莫西沙星0.5% W/V滴眼液,为期7天。所有参与者被允许同时在双眼涂抹泪液替代品(羧甲基纤维素钠0.5% W/V),每日三次。在第3天和第7天根据临床治愈率测量疗效,临床治愈率定义为没有任何结膜炎的眼部体征。通过患者报告的总体眼部不良事件来评估药物的安全性。妥布霉素组61例,莫西沙星组66例完成完整研究。两种药物的临床治愈率都很高,但莫西沙星在第3天的治愈率略高(56.06% vs 47.54%;P =0.37)和第7天(93.94% vs 88.52%;P =0.52)。妥布霉素组有1例轻度视力模糊,莫西沙星组有1例对眼睛有轻微刺激。总的眼部不良反应非常轻微,具有可比性。当使用硫酸妥布霉素0.3% W/V和莫西沙星0.5% W/V滴眼液治疗急性细菌性结膜炎时,每天4次,连续7天,副作用可忽略不计,作为经验疗法同样有效。相应的作者
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
1
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信